Ulta Beauty's brutal 14% selloff reveals deep cracks in the consumer discretionary facade as the post-pandemum vanity tr…

Ulta Beauty's disappointing earnings signal potential trouble for consumer discretionary stocks amid economic uncertaint…

SentinelOne's Q4 miss and weak guidance triggered a technical breakdown. Here's why the cybersecurity trade is losing mo…

SentinelOne's weak forecast is spooking investors. Is this a company-specific issue, or a sign of broader challenges for…

Ulta's 8% plunge signals deeper cracks in discretionary retail as the 'lipstick effect' faces its toughest test yet.

VRTX jumps 4% on Phase 3 trial success. Here's why long-term investors should view volatility as opportunity, not noise.

Oracle crushed Q3 with $1.79 EPS vs $1.70 expected, sparking a 9% rally as AI infrastructure fears fade. Here's your dat…

Vertex's 4% surge on kidney drug trial results highlights why long-term investors are finding shelter in this biotech gi…

Oracle's Q3 earnings crush expectations, proving its cloud-AI pivot is more than just smoke and mirrors. Here's why $ORC…

As $ORCL prepares to report Q3 earnings, the database giant must prove its cloud pivot can deliver growth amid tech sect…

While CASY eyes 27% earnings growth, investors should weigh inflation risks and margin pressures before Monday's report.

Casey's ($CASY) faces sky-high expectations with 27% projected EPS growth ahead of March 9 earnings, but regional risks …